A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years

A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MEDI3250 Compared to Placebo in Healthy Japanese Children Age 7 Years Through 18 Years

The study is designed to gather the efficacy, safety and tolerability data in Japanese children 7 to 18 years of age that would support approval of MEDI3250 in Japan.

Study Overview

• Status: Completed
• Conditions: Healthy Japanese Children Age 7 Years Through 18 Years
• Intervention / Treatment: Drug: Placebo; Drug: MEDI3250

Detailed Description

This randomized, double-blind, placebo controlled, multicenter study will enrol 1008 subjects. The study is designed to gather the efficacy, safety and tolerability data in Japanese children 7 through 18 years of age that would support approval of MEDI3250 in Japan.

For children age 7 years through 18 years, the recommended dosage schedule for intranasal administration is 0.2 mL (0.1 mL per nostril). For children age 7 years through 8 years not previously vaccinated against seasonal influenza, a second dose should be given after an interval of at least 4 weeks.

For the efficacy endpoint, data will be gathered on the incidence of laboratory-confirmed influenza-like illness in the two treatment arms. Laboratory-confirmed influenza-like illness would include cases of influenza diagnosed using culture-confirmation and/or PCR-based methods.

For the safety and tolerability endpoint, data will be gathered on solicited symptoms, AEs and SAEs.

Subject will be randomized 2:1 to receive MEDI3250 or placebo.

• Study Type: Interventional
• Enrollment (Actual): 1369
• Phase: Phase 3

Contacts and Locations

Study Locations

• Japan
  • Akashi-shi, Japan
    • Research Site
  • Chofu-shi, Japan
    • Research Site
  • Fuchu-shi, Japan
    • Research Site
  • Fujimi-shi, Japan
    • Research Site
  • Fukui-shi, Japan
    • Research Site
  • Fukuoka-shi, Japan
    • Research Site
  • Fukuroi-shi, Japan
    • Research Site
  • Funabashi-shi, Japan
    • Research Site
  • Gifu-shi, Japan
    • Research Site
  • Hatsukaichi-shi, Japan
    • Research Site
  • Hiroshima-shi, Japan
    • Research Site
  • Ichikawa-shi, Japan
    • Research Site
  • Isumi-shi, Japan
    • Research Site
  • Iwate-gun, Japan
    • Research Site
  • Katsushika-ku, Japan
    • Research Site
  • Kawasaki-shi, Japan
    • Research Site
  • Kisarazu-shi, Japan
    • Research Site
  • Kiyose-shi, Japan
    • Research Site
  • Kobe-shi, Japan
    • Research Site
  • Koga-shi, Japan
    • Research Site
  • Kumamoto-shi, Japan
    • Research Site
  • Kunitachi-shi, Japan
    • Research Site
  • Kuwana-shi, Japan
    • Research Site
  • Matsudo-shi, Japan
    • Research Site
  • Minato-ku, Japan
    • Research Site
  • Morioka-shi, Japan
    • Research Site
  • Nakano-ku, Japan
    • Research Site
  • Okayama-shi, Japan
    • Research Site
  • Ota-ku, Japan
    • Research Site
  • Sapporo-shi, Japan
    • Research Site
  • Sendai-shi, Japan
    • Research Site
  • Setagaya-ku, Japan
    • Research Site
  • Shinjuku-ku, Japan
    • Research Site
  • Shizuoka-shi, Japan
    • Research Site
  • Taito-ku, Japan
    • Research Site
  • Toshima-ku, Japan
    • Research Site
  • Tsu-shi, Japan
    • Research Site
  • Yokkaichi-shi, Japan
    • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 7 years to 18 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Age 7 through 18 years of age at the time of randomization.
2. A written informed consent should be obtained from the subject's legally acceptable representative, and a written informed assent should be obtained from the subject if possible.
3. Available for illness visits at clinic during the influenza surveillance period.
4. Ability of the legal representative to understand and comply with the requirements of the protocol．
5. Parent/guardian available by telephone, email or etc．
6. Females of childbearing potential, unless surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), has sterile male partner, is premenarchal, or practices abstinence, must have used an effective method of avoiding pregnancy (including oral, transdermal, or implanted contraceptives, intrauterine device, female condom with spermicide, diaphragm with spermicide, cervical cap with spermicide, or use of a condom with spermicide by the sexual partner) for 30 days prior to the first dose of investigational product, and must agree to continue using such precautions for 60 days after the final dose of investigational product.
7. A subject who is considered by the investigator to be at risk of pregnancy must also have a negative urine pregnancy test at screening and, if screening and Day 0 do not occur on the same day, on the day of vaccination prior to randomization. Investigator judgment is required to assess each subject's need for pregnancy testing.
8. Healthy by medical history and physical examination OR presence of stable underlying chronic medical condition for which hospitalization has not been required in the previous year.

Exclusion Criteria:

1. Subjects who were previously administered influenza vaccine in 2014-2015 influenza season
2. Previous randomisation in the present study
3. Participation in another clinical study with an investigational product during the last 3 month
4. Acute illness or evidence of significant active infection at randomization;
5. Fever ≥99.5°F (37.5°C) at randomization;

6. Any drug therapy from 15 days prior to randomization or expected drug therapy through 28 days post last dose with the exception of the following classes/types of medications, which are allowed:

   Contraceptives (change in contraceptive type or method is acceptable as long as guidelines are followed for prevention of pregnancy during change); Topical corticosteroids, calcineurin inhibitors, or antifungals for uncomplicated dermatitis; Chronic medications (including those taken on an as-needed basis) that have been well tolerated and were not initiated and/or did not have a dosage change within 90 days prior to randomization.

7. Current or expected receipt of immunosuppressive medications within a 28-day window around any dose, including an immunosuppressive dose of corticosteroids, which is defined as ≥20 mg/day of prednisone or its equivalent, given daily or on alternate days for ≥15 days (intranasal, intra-articular, and topical corticosteroids are permitted); Note: topical corticosteroids for uncomplicated dermatitis may be used throughout the study according to the judgment of the investigator; topical calcineurin inhibitors may be used in accordance with their package insert at entry and during study participation.
8. Any known immunosuppressive condition or immune deficiency disease including known or suspected infection with human immunodeficiency virus (HIV);
9. History of allergic disease or reactions likely to be exacerbated by any component of the investigational product including allergy to eggs, egg proteins, gentamicin, or gelatin or serious, life threatening, or severe reactions to previous influenza vaccinations;
10. Use of aspirin or salicylate-containing medications within 28 days prior to randomization or expected receipt through the entire study;
11. History of Guillain-Barré syndrome;
12. Use of antiviral agents with activity against influenza virus (including amantadine, rimantadine, oseltamivir, and zanamivir) within 28 days prior to first dose of investigational product or anticipated use of such agents in the study period;
13. Administration of any live virus vaccine within 30 days prior to enrolment, or if receipt of another live virus vaccine is expected within 30 days of any study vaccination;
14. Administration of any inactivated vaccine within 14 days prior to enrolment or if receipt of another inactivated vaccine is expected within 14 days of any study vaccination;
15. Receipt of any blood product within 90 days prior to vaccination or expected receipt during this study;
16. Pregnant or lactating female
17. Involvement in the planning and conduct of the study (applies to all AstraZeneca staff and staff at the study site as a legal representative)
18. Any condition that, in the opinion of the investigator, might interfere with the interpretation or evaluation of the vaccines.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: MEDI3250; MEDI3250 Nasal Spray	Drug: MEDI3250; MEDI3250
Placebo Comparator: Placebo; Placebo Nasal spray	Drug: Placebo; Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
the Incidence of Laboratory-confirmed Influenza Infection (Matched Strain)	The vaccine efficacy of MEDI3250 compared to placebo against the incidence of laboratory-confirmed influenza infection (matched strain)	through the end of the influenza surveillance period, up to end Apr (6 months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
the Incidence of Laboratory-confirmed Influenza Infection (Any Strain)	The vaccine efficacy of MEDI3250 compared to placebo against the incidence of laboratory-confirmed influenza infection (any strain)	through the end of the influenza surveillance period, up to end Apr (6 months)
the Incidence of Laboratory-confirmed Influenza Infection (Matched Strain, by Strain)	The vaccine efficacy of MEDI3250 compared to placebo against the incidence of laboratory-confirmed influenza infection (matched strain, by strain)	through the end of the influenza surveillance period, up to end Apr (6 months)

Collaborators and Investigators

• Sponsor: AstraZeneca
• Investigators: Principal Investigator: Masaki Yokohama, MD, Yokohama clinic; Principal Investigator: Toshiko Yamaguchi, MD, Yamaguchi Clinic; Principal Investigator: Haruo Maeta, MD, Maeta Pediatrics Clinic; Principal Investigator: Hideki Nakazawa, MD, HIGASHIKATSUYAMA nakazawa Naika allergy Internal Medicine; Principal Investigator: Atsushi Shibasaki, MD, Shibasaki internal medicine & Pediatrics Clinic; Principal Investigator: Yutaka Igarashi, MD, Igarashi Children's Clinic; Principal Investigator: Keiko Mitamura, MD, Eiju General Hospital; Principal Investigator: Satoshi Yamada, MD, Kyouai Clinic; Principal Investigator: Kiyoshi Niwa, MD, Niwa Family Clinic; Principal Investigator: Ryuta Ono, MD, Kanagawa Himawari Clinic; Principal Investigator: Eiji Kato, MD, Fukuiken Saiseikai Hospital; Principal Investigator: Toshikazu Takahashi, MD, Takahashi Clinic; Principal Investigator: Ryouta Yoshimura, MD, Yoshimura Children's Clinic; Principal Investigator: Hiroshi Taniguchi, MD, Taniguchi Pediatrics Clinic; Principal Investigator: Hidehisa Shinohara, MD, Shinohara Pediatrics Clinic; Principal Investigator: Michiko Tanabe, MD, Tanabe Pediatrics Clinic; Principal Investigator: Haruo Kuroki, MD, Sotobo Children's Clinic; Principal Investigator: Hirokazu Sato, MD, Sunrise Children's Clinic; Principal Investigator: Katsumi Yamada, MD, Yamada Clinic; Principal Investigator: Hiroshi Sakiyama, MD, Sakiyama Pediatric Clinic; Principal Investigator: Hiroji Okawa, MD, Okawa Children & Family Clinic; Principal Investigator: Junichi Ito, MD, Ito ENT Clinic; Principal Investigator: Masato Morimoto, MD, MORIMOTO ENT CLINIC; Principal Investigator: Masakazu Umemoto, MD, Umemoto Pediatric Clinic; Principal Investigator: Tadashi Matuda, MD, Matsuda Pediatrics Clinic; Principal Investigator: Sadayoshi Torigoe, MD, Aquair Medical Station; Principal Investigator: Shigeru Mori, MD, Momotaro Clinic; Principal Investigator: Yutaka Fujimaki, MD, Fujimaki Ent Clinic; Principal Investigator: Masaki Kato, MD, Kato Ear Nose Throat Clinic; Principal Investigator: Hisakuni Sekino, MD, Sekino Hospital; Principal Investigator: Toshikazu Nagakura, MD, Yoga Allergy Clinic; Principal Investigator: Ichiro Ogiwara, MD, Ogiwara Ent Clinic; Principal Investigator: Akitoshi Funato, MD, Medical corporation Seisyuukai Funato Clinic; Principal Investigator: Naohisa Hoshino, MD, Medical corporation Ryoshukai Kanauchi Medical Clinic; Principal Investigator: Munechika Noguchi, MD, Social medical corporation IHL ShinagawaEastOne Medical Clinic; Principal Investigator: Chiaki Noguchi, MD, Shinkoiwa Ekimae Sougou Clinic; Principal Investigator: Kimihiko Yukisada, MD, Yukisada Clinic for internal disease; Principal Investigator: Hiroshi Shimomura, MD, Medical corporation Junyokai Musashino General Clinic; Principal Investigator: Mitsuhiro Nemoto, MD, Nemoto-geka-seikeigeka; Principal Investigator: Naoki Kawai, MD, Kawai Naika Iin; Principal Investigator: Shigehiro Yazima, MD, Yajima Children's Clinic; Principal Investigator: Tetsuhiko Nagao, MD, Midorino Clinic; Principal Investigator: Kenjiro Nakamura, MD, Tenjin Sogo Clinic; Principal Investigator: Wataru Ikematsu, MD, Kobori Building Clinic; Principal Investigator: Shiro Kimura, MD, Kimura Shiro Clinic; Principal Investigator: Mieko Ueda, MD, Ueda Naika Clinic; Principal Investigator: Minako Iwaya, MD, Iwaya Children's Clinic; Principal Investigator: Motohisa Ikeda, MD, Ikeda Naika Clinic; Principal Investigator: Tetsunari Maeda, MD, Sakura Clinic

Study record dates

Study Major Dates

• Study Start: October 1, 2014
• Primary Completion (Actual): April 1, 2015
• Study Completion (Actual): April 1, 2015

Study Registration Dates

• First Submitted: October 13, 2014
• First Submitted That Met QC Criteria: October 17, 2014
• First Posted (Estimate): October 21, 2014

Study Record Updates

• Last Update Posted (Actual): April 4, 2017
• Last Update Submitted That Met QC Criteria: March 6, 2017
• Last Verified: February 1, 2017

More Information

Terms related to this study

• Keywords: Safety; Efficacy; Tolerability; MEDI3250; Japanese children
• Other Study ID Numbers: D2560C00006